Myocarditis and Pericarditis in Patients with COVID-19.
| Autor: | Shah JZ; Department of Cardiology and Cardiovascular Surgery, Heart Hospital, Hamad Medical Corporation, Doha, Qatar., Kumar SA; Department of Cardiology and Cardiovascular Surgery, Heart Hospital, Hamad Medical Corporation, Doha, Qatar., Patel AA; Department of Cardiology and Cardiovascular Surgery, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heart views : the official journal of the Gulf Heart Association [Heart Views] 2020 Jul-Sep; Vol. 21 (3), pp. 209-214. Date of Electronic Publication: 2020 Oct 13. |
| DOI: | 10.4103/HEARTVIEWS.HEARTVIEWS_154_20 |
| Abstrakt: | COVID-19 has been associated with a variety of cardiac manifestations. Myocarditis and pericarditis have been reported as one of the many cardiac manifestations in association with COVID-19. We describe below three cases of myocarditis, pericarditis with associated pericardial effusion and myopericarditis, respectively, in the setting of COVID-19. Although these entities may occur in isolation, they often occur in association to varying degrees. It could either be the initial diagnosis at the time of presentation or it could occur later in the course of COVID-19 infection. Pericarditis may occasionally be associated with significant pericardial effusion and tamponade requiring therapeutic pericardiocentesis. The assessment of pericardial effusion has been found to be exudative and is usually negative for SARS-CoV-2. Treatment of pericarditis with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids has proven to be safe in COVID-19. Myocarditis may present with severe left ventricular systolic dysfunction and cardiogenic shock requiring inotropes and mechanical circulatory support. Competing Interests: There are no conflicts of interest. (Copyright: © 2020 Heart Views.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|